Oxford study suggests multi-cancer blood test could accelerate diagnosis

An analysis of two-year follow-up data from the NHS SYMPLIFY trial suggests that a multi-cancer early detection (MCED) blood test could significantly reduce diagnostic delays for certain cancers. Published in *The Lancet Regional Health - Europe*, the findings indicate the test's potential to guide patients to appropriate investigations, especially for cancers with vague symptoms. This development could lead to earlier interventions and improved patient outcomes.